CTI BIOPHARMA CORP — key financial figures for fiscal year 2022 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2022)

$53.9M

Net Income/Loss (FY2022)

-$93.0M

Total Assets (FY2022)

$125.9M

Total Equity (FY2022)

-$17.6M

Cash Flows from Operating Activities (FY2022)

-$81.2M

Source: CTI BIOPHARMA CORP 10-K filing (FY2022). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.